Effect of anti-epileptic drugs on serum zinc and copper concentrations in epileptic patients

T. Kuzuya, T. Hasegawa, K. Shimizu, Toshitaka Nabeshima

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Serum concentrations for zinc and copper were determined in epileptic patients who had undergone one month of therapy with a mono-antiepileptic drug (mono-AED) (carbamazepine, CBZ; phenobarbital, PB; phenytoin, PHT; valproic acid, VPA). There were 114 epileptic patients and 30 healthy volunteers who participated in this study. Although zinc concentrations tended to decrease, there were significant increases in copper concentrations in patients who were treated with mono-AED) (CBZ, 32.9%; PB, 36.4%; PHT, 39.0%; VPA, 25.4%) when compared with healthy volunteers. There was no significant change in either zinc or copper concentrations among the four mono-AED groups. No dose-related changes could be observed either for zinc or copper concentrations. In conclusion, this study demonstrated that both zinc and copper concentrations in epileptic patients under chronic AED therapy differed somewhat from the control level, but remained within the normal range, indicating that there is no need to adjust serum concentrations of either of these trace elements in order to treat diseases related to them.

Original languageEnglish
Pages (from-to)61-65
Number of pages5
JournalInternational Journal of Clinical Pharmacology Therapy and Toxicology
Volume31
Issue number2
Publication statusPublished - 01-01-1993

Fingerprint

Zinc
Copper
Anticonvulsants
Serum
Pharmaceutical Preparations
Healthy Volunteers
Level control
Carbamazepine
Trace Elements
Valproic Acid
Phenytoin
Phenobarbital
Reference Values
Therapeutics

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology (medical)

Cite this

@article{6e94aaef6b2544b09ce4b45fdef234b9,
title = "Effect of anti-epileptic drugs on serum zinc and copper concentrations in epileptic patients",
abstract = "Serum concentrations for zinc and copper were determined in epileptic patients who had undergone one month of therapy with a mono-antiepileptic drug (mono-AED) (carbamazepine, CBZ; phenobarbital, PB; phenytoin, PHT; valproic acid, VPA). There were 114 epileptic patients and 30 healthy volunteers who participated in this study. Although zinc concentrations tended to decrease, there were significant increases in copper concentrations in patients who were treated with mono-AED) (CBZ, 32.9{\%}; PB, 36.4{\%}; PHT, 39.0{\%}; VPA, 25.4{\%}) when compared with healthy volunteers. There was no significant change in either zinc or copper concentrations among the four mono-AED groups. No dose-related changes could be observed either for zinc or copper concentrations. In conclusion, this study demonstrated that both zinc and copper concentrations in epileptic patients under chronic AED therapy differed somewhat from the control level, but remained within the normal range, indicating that there is no need to adjust serum concentrations of either of these trace elements in order to treat diseases related to them.",
author = "T. Kuzuya and T. Hasegawa and K. Shimizu and Toshitaka Nabeshima",
year = "1993",
month = "1",
day = "1",
language = "English",
volume = "31",
pages = "61--65",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "2",

}

Effect of anti-epileptic drugs on serum zinc and copper concentrations in epileptic patients. / Kuzuya, T.; Hasegawa, T.; Shimizu, K.; Nabeshima, Toshitaka.

In: International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 31, No. 2, 01.01.1993, p. 61-65.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of anti-epileptic drugs on serum zinc and copper concentrations in epileptic patients

AU - Kuzuya, T.

AU - Hasegawa, T.

AU - Shimizu, K.

AU - Nabeshima, Toshitaka

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Serum concentrations for zinc and copper were determined in epileptic patients who had undergone one month of therapy with a mono-antiepileptic drug (mono-AED) (carbamazepine, CBZ; phenobarbital, PB; phenytoin, PHT; valproic acid, VPA). There were 114 epileptic patients and 30 healthy volunteers who participated in this study. Although zinc concentrations tended to decrease, there were significant increases in copper concentrations in patients who were treated with mono-AED) (CBZ, 32.9%; PB, 36.4%; PHT, 39.0%; VPA, 25.4%) when compared with healthy volunteers. There was no significant change in either zinc or copper concentrations among the four mono-AED groups. No dose-related changes could be observed either for zinc or copper concentrations. In conclusion, this study demonstrated that both zinc and copper concentrations in epileptic patients under chronic AED therapy differed somewhat from the control level, but remained within the normal range, indicating that there is no need to adjust serum concentrations of either of these trace elements in order to treat diseases related to them.

AB - Serum concentrations for zinc and copper were determined in epileptic patients who had undergone one month of therapy with a mono-antiepileptic drug (mono-AED) (carbamazepine, CBZ; phenobarbital, PB; phenytoin, PHT; valproic acid, VPA). There were 114 epileptic patients and 30 healthy volunteers who participated in this study. Although zinc concentrations tended to decrease, there were significant increases in copper concentrations in patients who were treated with mono-AED) (CBZ, 32.9%; PB, 36.4%; PHT, 39.0%; VPA, 25.4%) when compared with healthy volunteers. There was no significant change in either zinc or copper concentrations among the four mono-AED groups. No dose-related changes could be observed either for zinc or copper concentrations. In conclusion, this study demonstrated that both zinc and copper concentrations in epileptic patients under chronic AED therapy differed somewhat from the control level, but remained within the normal range, indicating that there is no need to adjust serum concentrations of either of these trace elements in order to treat diseases related to them.

UR - http://www.scopus.com/inward/record.url?scp=0027535029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027535029&partnerID=8YFLogxK

M3 - Article

C2 - 8458677

AN - SCOPUS:0027535029

VL - 31

SP - 61

EP - 65

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 2

ER -